News about "Novo Nordisk"

Vivani Medical and Novo Nordisk Sign Agreement to Evaluate Long-Acting Semaglutide Implant for Weight Management

Vivani Medical has entered into an agreement with Novo Nordisk to evaluate NPM-139, its ultra long-acting semaglutide implant for chronic weight management. The implant aims to offer a convenient once- or twice-yearly treatment option, with Phase 1 clinical trials expected to commence in mid-2026.

Novo Nordisk | 09/07/2026 | By News Bureau

UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis

The UK's Medicines and Healthcare products Regulatory Agency has conditionally approved Novo Nordisk's Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, subject to ongoing confirmatory clinical data.

Novo Nordisk | 06/07/2026 | By News Bureau

Shantha Biologics Announces Strategic Cartridge Fill-Finish Collaboration

Shantha Biologics has announced a cartridge fill-finish collaboration with Novo Nordisk, strengthening high-quality biologics manufacturing and global healthcare partnerships.

Novo Nordisk | 04/07/2026 | By News Bureau

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Novo Nordisk | 10/06/2026 | By News Bureau |  169

Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes

Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.

Novo Nordisk | 08/06/2026 | By News Bureau

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US

UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.

Novo Nordisk | 04/06/2026 | By News Bureau

Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders

Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.

Novo Nordisk | 13/05/2026 | By News Bureau |  110

Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment

FDA approves Novo Nordisk’s Wegovy HD (semaglutide 7.2 mg), a higher-dose weekly injection delivering significant weight loss, supported by strong Phase III trial outcomes.

Novo Nordisk | 21/03/2026 | By News Bureau |  151

FDA Clears Novo Nordisk's Sogroya for Three New Paediatric Uses

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Sogroya for three additional paediatric indications, expanding its use in children aged 2.5 years and older and reinforcing its position as the only once-weekly, long-acting growth hormone with the broadest approved label.

Novo Nordisk | 02/03/2026 | By News Bureau |  171

Novo Nordisk Signs USD 2.1 Billion Pact with Vivtex to Develop Oral Obesity Therapies

Novo Nordisk has entered into a strategic collaboration with US-based Vivtex to develop next-generation oral biologic therapies for obesity, diabetes and related metabolic conditions.

Novo Nordisk | 27/02/2026 | By Darshana |  144